In a laboratory in Kampala, a technician logs a blood sample from a patient whose fever does not fit the usual pattern. Malaria has been ruled out. The sample moves to a national public health laboratory, and within hours a result is shared with partners in London. Most weeks nothing comes of it. The weeks that matter are those in which the sample is positive for something unfamiliar, because the speed of that answer decides whether an outbreak remains a local event or becomes an international one.

The recent visit of the Foreign, Commonwealth and Development Office's Chief Scientific Adviser to Uganda, which included assessments of the MRC/UVRI and LSHTM Research Unit and the National Public Health Laboratory, was presented as diplomacy. It is better read as an audit of an asset. Uganda has managed repeated Ebola outbreaks, including Sudan virus in 2022, and decades of UK scientific funding are part of the reason they stayed contained.

The connection to the NHS is real but indirect, and it should be described as such. A haemorrhagic fever in East Africa does not reach an English emergency department by default, and the UK's network of high consequence infectious disease units exists for precisely that unlikely event. The relevance lies in what surveillance abroad buys at home, which is time. Early genomic information allows the UK Health Security Agency to adjust border advice, diagnostics and clinical guidance before a single patient presents. Covid demonstrated what follows when that time is missing.

The difficulty is that this protection is paid for from a budget under pressure. The government has committed to reducing official development assistance to 0.3 per cent of gross national income by 2027, with the released funds directed towards defence. Global health programmes now compete with every other line for what remains. Research partnerships of this kind are slow to build and slower to rebuild. A laboratory network that loses trained staff for two years does not regain them in two months. A saving recorded in one department can become a liability in another, and the NHS is usually where liabilities land.

That matters because the health service has little slack to absorb a shock. Waiting lists remain above seven million, general and acute bed occupancy frequently exceeds the 85 per cent level generally regarded as safe, and corridor care has become a fixture of winter planning. Isolation rooms, infection control nurses and critical care beds come from the same constrained pool as elective recovery. A modest infectious disease event, one that a better-resourced system would barely notice, could force cancellations and undo the productivity gains on which ministers have staked their credibility.

There is an industrial dimension as well. The Research Unit and its London partners generate sequencing data, trial sites and clinical cohorts from populations that are poorly represented in most datasets. The government's life sciences strategy rests on British strength in genomics and clinical research, and that strength was built through international networks as much as domestic ones. Manufacturers developing diagnostics and vaccines depend on access to field sites where pathogens actually circulate. Data sharing terms and fair credit for African scientists will decide whether that access endures, and both need political attention rather than scientific goodwill alone.

NHS leaders rarely sit in rooms where aid allocations are decided, and few would regard it as their remit. They should. Trusts and integrated care boards write resilience plans on the assumption that national early warning functions will hold. Policymakers, for their part, should enter global health security spending on the NHS risk register and cost it accordingly. A pound spent on a Kampala laboratory is hard to value precisely, but the price of its absence can be estimated from the cost of a single lost month of elective activity.

The High Commissioner's account of a scientific visit reads as routine diplomacy. Its significance is that Britain's first warning of the next outbreak may well come from a technician in Uganda, and whether that warning arrives in time depends on decisions taken in Whitehall long before any patient reaches a ward.

‍